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Background: In the past many regions of Bangladesh were hyperendemic for malaria. Malaria control in the
1960s to 1970s eliminated malaria from the plains but in the Chittagong Hill Tracts remained a difficult to control
reservoir. The Chittagong Hill Tracts have areas with between 1 and 10% annual malaria rates, predominately
90-95% Plasmodium falciparum. In Southeast Asia, multiplicity of infection for hypo-endemic regions has been
approximately 1.5. Few studies on the genetic diversity of P. falciparum have been performed in Bangladesh.
Anderson et al. performed a study in Khagrachari, northern Chittagong Hill Tracts in 2002 on 203 patients and
found that parasites had a multiplicity of infection of 1.3 by MSP-1, MSP-2 and GLURP genotyping. A total of 94% of
the isolates had the K76T Pfcrt chloroquine resistant genotype, and 70% showed the N86Y Pfmdr1 genotype.
Antifolate drug resistant genotypes were high with 99% and 73% of parasites having two or more mutations at the
dhfr or dhps loci.
Methods: Nested and real-time polymerase chain reaction (PCR) methods were used to genotype P. falciparum
using antigenic polymorphic markers and to study anti-malarial drug resistance markers in malaria endemic areas of
Bangladesh.
Results: The analysis of polymorphic and drug resistant genotype on 33 paired recrudescent infections after drug
treatment in the period 2004 to 2008 in the Chittagong Hill Tracts, which is just prior to countrywide provision of
artemisinin combination therapy. Overall the multiplicity of infection for MSP-1 was 2.7 with a slightly smaller
parasite diversity post-treatment. The 13 monoclonal infections by both GLURP and MSP-1 were evenly divided
between pre- and post-treatment. The MSP-1 MAD block was most frequent in 66 of the samples. The prevalence
of the K76T PfCRT chloroquine resistant allele was approximately 82% of the samples, while the resistant Pfmdr1
N86Y was present in 33% of the samples. Interestingly, the post-treatment samples had a small but significantly
higher frequency of the sensitive PfCRT alleles by RT-PCR.
Conclusion: The parasite population retains high population diversity despite hypo-endemic transmission with
retention, but decrease in the chloroquine-resistant allele and Pfmdr1 resistant alleles in the Chittagong Hill Tracts
of Bangladesh.
Keywords: Malaria, Genotype, Anti-malarial drug resistance markers, Plasmodium falciparum, MSP-1 and pfcrt* Correspondence: jakter@icddrb.org
1ICDDR,B, GPO Box 128, Dhaka 1000, Bangladesh
Full list of author information is available at the end of the article
© 2012 Akter et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Akter et al. Malaria Journal 2012, 11:386 Page 2 of 6
http://www.malariajournal.com/content/11/1/386Background
Malaria is a major health problem in several Southeast
Asian countries and is exacerbated by the development
and spread of anti-malarial drug resistance. A recent re-
port from WHO in 2009 described about 55,000
laboratory-confirmed malaria cases with more than
40 deaths per year in Bangladesh [1]. Estimated non-
confirmed malaria cases are in the hundreds of thou-
sands. The total annual mortality has decreased from
500 per annum the decade before. This may be due to
the change to artemisinin-based combination therapy
and greater use of malaria rapid diagnostic tests.
Resistance to chloroquine, the most widely used and
affordable anti-malarial drug, had contributed to
increased mortality and morbidity caused by Plasmodium
falciparum infections during the 1990s in Bangladesh [2,3].
So far, very limited data are available on the efficacy of mal-
aria treatments and the current situation of anti-malarial
drug resistance in Bangladesh. In addition, only a few stud-
ies on the molecular characterization of the local parasite
population have been performed. Anderson et al. [4] per-
formed a study in Khagrachari, northern Chittagong Hill
Tracts in 2002 on 203 patients and found that para-
sites had a multiplicity of infection of 1.3 by MSP-1,
MSP-2 and GLURP genotyping. A total of 94% of
the isolates had the K76T Pfcrt chloroquine resistant
genotype, and 70% showed the N86Y Pfmdr1 geno-
type. Antifolate drug resistant genotypes were high
with 99% and 73% of parasites having two or more
mutations at the dhfr or dhps loci [4].
It is very difficult to genotype malaria parasites accur-
ately in areas of high transmission, where patients are
often infected with multiple parasite strains. It is gener-
ally agreed that if any parasites in the pre-treatment
sample persist after therapy, the subject is considered to
have a recrudescence. However, when multiple parasite
strains are present, the probability increases that at least
one strain in the pre-treatment and recurrent samples
may have the same genotype, leading to misclassification
of a new infection as a recrudescence. Others have noted
the importance of taking into account misclassification
of new infections as recrudescence [5,6] but this has
often been overlooked when interpreting genotyping-
adjusted results from anti-malarial clinical trials [7]. Mis-
classification of a new infection as a recrudescence can
be decreased by using multiple genotyping markers [8].
The purpose of the study was to genotype P. falciparum
using antigenic polymorphic markers and to study anti-
malarial drug resistance markers of the P. falciparum para-
sites in malaria endemic areas of Bangladesh. The study
samples collected from three clinical trials conducted in
malaria endemic areas of Bangladesh from 2004 to 2008.
This study also provides a follow-up to the analysis per-
formed in Khagrachari in 2002 [4] and also another analysisbefore countrywide artemisinin combination therapy began
in 2007.
Methods
Study site and samples
Samples were collected from three clinical trials, study-
ing anti-malarial drug efficacy, one conducted in Cox’s-
Bazar district and another two in Banderban district, in
the Chittagong Hill Tracts during 2004, 2005 and 2008
respectively. The study conducted in 2004 by Haque
et al. on the efficacy of quinine plus sulphadoxine-pyri-
methamine, in a situation where chloroquine was the
first-line therapy, showed a treatment failure rate after
PCR adjustment of 11.7% for Q+SP trial. In the year of
2005, artemether-lumefantrine was first-line therapy but,
due to limited data on ACT efficacy in Bangladesh,
Thriemer et al. conducted study on ACT efficacy and
found a failure rate after PCR adjustment of 5.7% for
ACT. Similarly, artemisinin-based combination (ACT)
was first-line therapy in 2008 when a study conducted
on the azithromycin plus artesunate showed a failure
rate after PCR adjustment of 5.4% for the azithromycin-
artesunate trial.
Samples were taken at Day 0 (pre-treatment) and at
the day of recurrent parasitaemia (post-treatment) dur-
ing 42 days’ follow-up. A total of 33 patients showed re-
appearance of parasites from the above-mentioned three
studies and details of the studies were already published
[9-11].
Blood collection and microscopy
Venous blood samples were collected in an EDTA tube
for microscopic examination and DNA extraction.
Giemsa-stained blood films obtained from the patients
were examined by light microscopy under an oil-
immersion objective. Parasitaemia was estimated by
counting the number of asexual forms of P. falciparum
corresponding to 200 leukocytes in the thick blood film.
The parasite density was calculated by assuming a
leukocyte count of 8,000/μl blood [12]. Geometric mean
parasite densities were not significantly higher (p >0.05)
in patients who later showed reappearance of parasites
than in patients who were classified as ACPRs and geo-
means were comparable.
Molecular analyses
DNA extraction and nested PCR
Blood samples were stored at −20°C prior to DNA ex-
traction. Genomic DNA was extracted from a total of
200 μl whole blood per patient using the Qiagen DNA
extraction kit (QIAGEN, USA) according to manufac-
turer's instructions. Nested polymerase chain reaction
(PCR) genotyping was performed both for the variable
block 2 regions of merozoite surface protein-1 (MSP-1),
Table 1 Oligonucleotides used in this study (listed 50 to 30)
Name Sequence
pfcrt F 50-TGT GCT CAT GTG TTT AAA CTT-30
pfcrt R 50-GGA TGT TAC AAA ACT ATA GTT ACC-30
pfcrt 76-CVMNK Texas- TGT GTA ATG AAT AAA ATT TTT GCT AA
pfcrt 76-CVIET FAM- TGT GTA ATT GAA ACA ATT TTT GCT AA
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assess potential multiplicity of P. falciparum infection
[13]. Paired pre-treatment and post-treatment samples
were analysed using parasite loci that exhibit repeat
numbers of polymorphisms to distinguish true treatment
failures from new infections.
Briefly, block 2 of MSP-1 and region II of GLURP
were amplified by two rounds of PCR using primers
and amplification conditions previously described by
Snounou and others [14]. Ten microlitres of the PCR
products were resolved by electrophoresis on a 2% agarose
gel and sized against 50-basepair (bp) molecular weight
marker (New England Biolabs, Beverly, MA, USA).
The banding pattern of the post-treatment parasites
was compared with matched pre-treatment samples.
Post-treatment and primary infection parasites showing
identical bands were considered a true treatment failure,
while non-identity indicated a new infection.
Point mutations in the P. falciparum chloroquine re-
sistance transporter (Pfcrt) gene and in the P. falciparum
multidrug resistance 1 gene (Pfmdr1) were analysed by
PCR-RFLP methods as described previously [15,16].
Multiplex-real-time PCR was performed and compared
with the PCR-RFLP result for K76T in pre-treatment
and post-treatment samples.Real-time PCR and pfcrt haplotype analysis
Multiplex real-time PCR was performed using a BioRad
CFX 96 Multicolor Real time Detection System thermo-
cyler (Bio-Rad, Hercules, CA). The reaction used IQTable 2 Parasite genotypes based on polymerase chain react












K1 6 19 10
MAD 8 25 12
R033 4 20 13
GLURP 6 32* 6
CRT-RFLP 2 33 6
MDR1 2 33 10
* Note: one of paired samples in baseline has not amplified for GLURP.powermix (BioRad) with 0.2 μM primer and probes, 1 μl
DNA for controls and 2 μl blood DNA for sample in a
final volume of 10 μl. All reactions were run in dupli-
cate. Real-time PCR cycling conditions consisted of an
initial denaturation step (5 min at 95°C), followed by 40
amplification cycles (10 sec at 95°C; 30 sec at 52°C; 30
sec at 65°C). 3D7 and W2 strains were used as positive
controls for K76 and 76T respectively. Primers and
probes were designed to detect K76T mutation asso-
ciated chloroquine (CQ) resistance by TagMan multiplex
real-time PCR assay. Probes are crt76-CVMNK (CQ
sensitive), crt76-CVIET (CQ resistant) in Southeast Asia
and Africa (Old World) [17]. Probes were also designed
to bind separately with the sensitive and resistant type
and data were analysed on the basis of Ct value (thresh-
old cycle) and in relation to the relative fluorescence
unit (RFU) for the respective haplotype. The commonly
used Ct value (threshold cycle) was calculated as the
intersection of a line drawn through the baseline and a
line drawn through the rise line. Ct estimates made
using this method were found to be more accurate and
consistent than those reported by the instrument control
software. A cut-off for RFU was determined by end-
point analysis in accordance with the manufacturer’s
instructions. The sequence of primers and probes is
given in Table 1.
Results
Genotyping using MSP-1 and GLURP markers
A total of 33 sample pairs were collected from patients
who failed anti-malarial drug treatment and were suc-
cessfully analysed for genetic diversity using msp-1 and
glurp loci. Amplification products of the MSP-1 allelic
family K1 was positive in 36 (54%) of the 66 samples,
and yielded six different allele fragments (150–280 bp)
with a predominate 200 bp allele (Table 2 and Figure 1).
The MSP-1 allelic family MAD20 was detected in
44 (66%) samples and produced eight different allele
fragments (130–300 bp) with a predominant 200 bpion (PCR) products of isolates of Plasmodium falciparum











3.0 33 26 2.3 2.7
1.5 17 10 1.6 1.6
1.5 19 11 1.6 1.5
1.6 13 7 1.5 1.6
1.2 33 5 1.2 1.2
1.2 33 3 1.1 1.1
1.3 33 3 1.1 1.2
Figure 1 Distribution of merozoite surface protein-1 (msp-1)
polymorphic loci of Plasmodium falciparum from patient
isolates.
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samples, and produced amplification products of four
different sizes with a predominant 150 bp fragment.
Within MSP-1 allelic families MAD 20 showed higher
frequency of PCR positivity and alleles than K1 and
RO33 in total samples. The region II of glurp was
detected in all of the samples and produced six different
fragments (600–1,100 bp) with a predominant 900 bp
allele (Figure 2). MSP-1 was more diverse than glurp −1
with 192 possible alleles versus 6, when the specific loci
of these genes that were assessed. GLURP indicated
monoclonal infections in 83% of the samples partially
because of the frequency of the 900 bp allele of glurp at
close to half of genotypes 37/76 (49%), while msp-1 indi-
cated monoclonal in only 20%. The frequency of the pre-
dominant msp-1 alleles were −17/56 (30%) for K1, 29/67
(43%) for MAD-20 and 33/52 (63%) for Ro33. K1 andFigure 2 Alllelic distribution of the merozoite surface protein-1 (msp-
from patient isolates.MAD had more normal distribution of allele numbers
while Ro33 and glurp had predominance of single allele
frequency. The most common genotype was K1-200 bp
and glurp −900 bp, which occurred in five of 66 samples.
This would equate to at most a 8% chance of finding a
similar genotype in pre- and post-treatment samples
given a re-infection rather than a recrudescent infection.
The multiplicity of infection was 2.7 for all three msp-1
blocks together and 1.5-1.6 individually, while glurp had
a similar MOI of 1.2 to the 2 allele RFLP of Pfcrt and
Pfmdr1 (Table 2).Complexity of genotypes in pre- and post-treatment
samples
Analysis of the genetic diversity in 33 paired isolates
using msp-1 and glurp showed that msp-1 had a higher
MOI of 3.0 pre-treatment versus 2.3 post-treatment. The
individual msp-1 blocks and glurp all had similar pre- or
post-treatment MOI. Pre-treatment 27 (81%) and six
(18%) of the 33 samples were polymorphic for msp-1 or
glurp, respectively, which was similar to post-treatment
MOI (Table 2). There were three (5%) samples with a
maximum of six genotypes using each of the MSP-1
blocks.
Persistent of identical alleles for GLURP pre- or post-
treatment occurred in 22/33 samples and in 20 of
33 MSP-1, while in both in 14 of 33. Four paired
samples were completely identical with even more than
one msp-1 alleles present at both times. Five of 33 pairs
had completely different alleles for both msp-1 and glurp.
Novel allele present in 13 cases of the post-treatment
samples that was not present in the pre-treatment1) and glutamate-rich protein (glurp) of Plasmodium falciparum
Table 3 Classification by PCR genotyping method of post-treatment isolates
Parasites genotypes PfCRT K76T RFLP PfCRT K76T RTPCR MDR1 N86Y RFLP MDR1 Y184F RFLP
Pre Tx Post Tx Pre Tx Post Tx Pre Tx Post Tx Pre Tx Post Tx
Sensitive 4 8 1 9 18 23 31 27
Sensitive and resistant 6 3 5 1 10 3 1 1
Resistant 23 21 27 23 5 7 1 5
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ment in 11 cases of the post-treatment samples.
Prevalence of Plasmodium falciparum drug resistance
markers
Molecular analysis of anti-malarial drug resistance mar-
kers, such as Pfcrt and Pfmdr-1, by PCR-restriction frag-
ment length polymorphisms (RFLP) in pre-treatment
and post-treatment samples showed a high prevalence of
mutant Pfcrt K76T 54/66 (82%) and a low prevalence
of mutant Pfmdr1 N86Y 25/66 (33%) and mutant Y184F
8/66 (12%). Among the 33 paired samples, nine and
13 were heterozygous for Pfcrt and Pfmdr1 (Table 3).
By RFLP the post-treatment prevalence of only sensitive
Pfcrt was doubled from four to eight while any sensitive
were 10 to 11.
The Pfcrt RT-PCR agreed with post-treatment RFLP
with more variance on the pre-treatment alleles. The
discordance was RFLP overcalling or undercalling com-
bined sensitive and resistant alleles in the sample six of
eight times.
The wild type Pfmdr1 alleles at position 86 and 184
was present in 36/66 of the samples, an additional six
had wild type N86 with resistant Y184F and 22 samples
had resistant N86Y with sensitive Y184. Only two sam-
ples were resistant at both amino acids. The double sen-
sitive allele and the 184 resistant allele have been
associated with more chloroquine sensitivity, but more
resistance to mefloquine or artemisinin derivatives [18].
Discussion
The findings on genetic diversity based on the poly-
morphic genes msp-1 and glurp of P. falciparum isolates
from a malaria-endemic region of Bangladesh, comple-
menting earlier work in a different location [1,8]. Multi-
plicity of infection with MSP-1 is slightly higher. The
glurp RFLP did not add much to genotyping with lower
frequency of diverse alleles. The post-treatment MOI
was slightly less than pre-treatment, this may be due to
clearance of sensitive strains through following treat-
ment. The somewhat higher population diversity is sur-
prising for the level of endemic malaria but may reflect
recent larger diversity with meso-endemic malaria.
The chloroquine-resistant allele appears to be decreas-
ing slightly in frequency just before the advent of wide-
spread use of the artemisinin derivatives. The highpopulation diversity with sensitive Pfcrt may translate
into return of the chloroquine-sensitive genotype given
that the resistant genotype does not appear to be fixed
in the population.
Despite a slight discordance between RFLP and
RT-PCR for the Pfcrt alleles the greater sensitivity of
detection and ease of use with an existent RT-PCR
machine makes the RT-PCR preferable.
This study shows the diversity and complexity of the
P. falciparum population in malaria endemic areas of
Bangladesh prior to deployment of country-wide artemi-
sinin combination therapy. The approach used in this
study could be used in addition to other molecular
methods as a part of a surveillance programme for mon-
itoring drug resistance patterns in malaria infections.Conclusion
The parasite population retains a high population diver-
sity despite hypo-endemic transmission with retention,
but decrease in the frequency of the chloroquine-
resistant allele and Pfmdr1 resistant alleles.
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